DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Definium Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$32.97+0.87 (+2.71%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
Definium Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Medicinal Chemicals & Botanical Products companies for comparison
Valuation
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Market Cap | $4.43B | $197.05M |
| Enterprise Value | $3.38B | $106.56M |
| PB Ratio | 4.82 | 2.14 |
| P/TBV Ratio | 4.93 | 2.46 |
Income (trailing twelve months)
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$227.54M | -$21.44M |
| Net Income | -$353.79M | -$22.46M |
| EBITDA | -$227.54M | -$16.91M |
| EPS (Diluted) | -$3.43 | -$0.83 |
Returns
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -64.1% | -53.1% |
| Return on Assets (ROA) | -51.3% | -41.0% |
| Return on Capital Employed (ROCE) | -23.8% | -37.8% |
Balance sheet
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.08B | $62.42M |
| Total Debt | $36.47M | $120.13M |
| Net Cash (Debt) | $1.05B | $15.68M |
| Net Cash Per Share | $7.80 | $0.65 |
| Equity (Book Value) | $918.68M | $48.79M |
| Book Value Per Share | $6.84 | $1.36 |
| Tangible Book Value | $898.76M | $23.06M |
| Working Capital | $934.90M | $75.77M |
Financial position
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.95 | 3.30 |
| Quick Ratio | 6.89 | 2.39 |
| Debt / Equity | 0.04 | 0.51 |
| Interest Coverage | -45.33 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$167.95M | -$12.35M |
Efficiency
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$3.37M | -$732.08K |
| Employee Count | 105 | 73 |
Dividends and yields
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -7.99% | -21.2% |
Shares
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 134,367,000 | 59,128,900 |
| Shares Change (YoY) | 20.7% | 11.1% |
| Shares Change (QoQ) | 29.1% | 0.54% |
| Float | 129,853,000 | 48,744,500 |
| Shares Held by Insiders | 3.36% | 11.8% |
| Shares Held by Institutions | 85.4% | 59.4% |
Scores
| Measure | Definium Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 12.99 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Definium Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.